WO2023246680 - ACTIVATORS OF COAGULATION FACTOR X AND FORMULATIONS THEREOF FOR TREATING BLEEDING DISORDERS
National phase entry:
Publication Number
WO/2023/246680
Publication Date
28.12.2023
International Application No.
PCT/CN2023/100987
International Filing Date
19.06.2023
Title **
[English]
ACTIVATORS OF COAGULATION FACTOR X AND FORMULATIONS THEREOF FOR TREATING BLEEDING DISORDERS
[French]
ACTIVATEURS DU FACTEUR DE COAGULATION X ET FORMULATIONS DE CEUX-CI POUR LE TRAITEMENT DE TROUBLES HÉMORRAGIQUES
Applicants **
JIANGSU BIOJETAY BIOTECHNOLOGY CO.,LTD.
Inventors
ZHOU, Zan
WANG, Xiaomin
WANG, Bingzhang
LIU, Junyong
Priority Data
PCT/CN2022/099820
20.06.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5533 | |
| EPO | Filing, Examination, Granting | 125197 | |
| Japan | Filing, Examination, Granting | 4903 | |
| South Korea | Filing, Examination, Granting | 9198 | |
| USA | Filing, Examination, Granting | 25790 |
Total:
170,621
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are compositions (e.g., pharmaceutical compositions) of coagulation factor X activator (FX activator, e.g., RVV-X) comprising sucrose, histidine, polysorbate 20, and mannitol, and uses of FX activators (e.g., RVV-X) or compositions (e.g., pharmaceutical compositions) thereof for treating a bleeding disorder (e.g., hemophilia) in an individual (e.g., human).[French]
L'invention concerne des compositions (par exemple, des compositions pharmaceutiques) de l'activateur du facteur de coagulation X (activateur FX, par ex., RVV-X) comprenant du saccharose, de l'histidine, du polysorbate 20 et du mannitol, ainsi que des utilisations d'activateurs FX (par ex., RVV-X) ou de compositions (par ex., des compositions pharmaceutiques) de ceux-ci pour traiter un trouble de saignement (par ex., l'hémophilie) chez un individu (par ex., un être humain).